Healthcare
Spencer Pharmaceutical Inc.(SPPH)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 12, 2026
- Market Cap
- —
- Revenue Growth
- -100.0%
- EPS Growth
- +66.7%
- Dividend Yield
- 0.0%
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Spencer Pharmaceutical Inc. (SPPH) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +66.7%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +66.7%, free cash flow +71.3% with operating margin 0.0% and ROIC 21.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SPPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +66.7%, with operating margin around 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SPPH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SPPH Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SPPH and SPY.
Company Overview
Spencer Pharmaceutical Inc.
Other OTC
Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America and Europe. The company was incorporated in 1998 and is based in Boston, Massachusetts.
- Leadership
- Maximilien Arella
- IPO Date
- Feb 7, 2023
- Employees
- 2
- Street Address
- 8 Faneuil Hall Marketplace
- Mailing
- Boston
- Region
- Boston, US
- Reporting Currency
- USD
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- 0.0
Growth
- Revenue
- -100.0%
- EPS
- +66.7%
- Free Cash Flow
- +71.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -50.2%
- ROIC
- 21.5%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 0.79
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.